Lyell Immunopharma (LYEL) Gains from Investment Securities (2020 - 2024)

Lyell Immunopharma has reported Gains from Investment Securities for 5 years, with the latest figure at -$13.0 million in Q4 2024.

• Quarterly Gains from Investment Securities changed N/A year-over-year to -$13.0 million in Q4 2024, while the trailing twelve-month figure through Sep 2024 was $13.0 million (up 44.62% YoY) and the FY2023 annual result came in at $12.9 million, up 1111.15% from the prior year.
• Gains from Investment Securities eased to -$13.0 million in Q4 2024 per LYEL's latest filing, from $13.0 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $36.4 million in Q4 2021 and troughed at -$13.0 million in Q4 2024.
• A 5-year average of $4.2 million and a median of $78500.0 in 2021 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2021 and 2022: Gains from Investment Securities surged 130100.0% in 2021, then plunged 110.8% in 2022.
• Over 5 years, Gains from Investment Securities stood at -$28000.0 in 2020, then soared by 130100.0% to $36.4 million in 2021, then slumped by 110.8% to -$3.9 million in 2022, then jumped by 174.32% to $2.9 million in 2023, then slumped by 544.78% to -$13.0 million in 2024.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered -$13.0 million, $13.0 million, and $2.9 million for Q4 2024, Q1 2024, and Q2 2023 respectively.